Lurbinectedin is a chemotherapy drug that has shown promising results in enhancing other therapies for the treatment of various cancers. It works by inhibiting the activity of RNA polymerase II, which is an enzyme that plays a crucial role in the transcription of DNA into RNA. This inhibition leads to the disruption of the cancer cell's ability to repair DNA damage, ultimately resulting in cell death [2].

One study found that combining lurbinectedin with the chemotherapy drug doxorubicin resulted in a significant increase in tumor growth inhibition in mice with sarcomas compared to treatment with either drug alone [3]. Another study showed that combining lurbinectedin with the immunotherapy drug pembrolizumab resulted in a higher response rate and longer progression-free survival in patients with small cell lung cancer compared to treatment with pembrolizumab alone [1].

In addition to enhancing the effectiveness of other therapies, lurbinectedin has also been found to have a favorable safety profile. The most common side effects reported in clinical trials were nausea, fatigue, and decreased appetite [2].

Overall, the combination of lurbinectedin with other therapies has shown promising results in the treatment of various cancers. Further research is needed to determine the optimal combinations and dosages for maximum efficacy and minimal side effects.

Sources:
[1] https://www.drugpatentwatch.com/p/tradename/LURBINECTEDIN
[2] https://medlineplus.gov/druginfo/meds/a620049.html
[3] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4795692/